Early Protection Against Heterologous SIV Challenge in Macaques
Author Information
Author(s): Neil Berry, Claire Ham, Edward T. Mee, Nicola J. Rose, Giada Mattiuzzo, Adrian Jenkins, Mark Page, William Elsley, Mark Robinson, Deborah Smith, Deborah Ferguson, Greg Towers, Neil Almond, Richard Stebbings
Primary Institution: Division of Retrovirology, National Institute for Biological Standards and Control (NIBSC), Health Protection Agency (HPA), South Mimms, Potters Bar, Hertfordshire, United Kingdom
Hypothesis
Can live attenuated SIV vaccines provide early protection against heterologous SIV challenges in Mauritian cynomolgus macaques?
Conclusion
The study demonstrated potent protection against SIVsmE660 challenge in macaques after just three weeks of vaccination with SIVmacC8.
Supporting Evidence
- 6 out of 8 macaques showed no evidence of SIVsmE660 superinfection after vaccination.
- Protection was observed as early as 3 weeks post-vaccination.
- Statistically significant reductions in peak and persisting viraemia were noted in vaccinated macaques compared to controls.
- Vaccine virus persisted in lymphoid tissues of protected macaques.
Takeaway
Researchers found that a vaccine can help protect monkeys from a virus after only three weeks, which is really fast for a vaccine to work.
Methodology
Macaques were vaccinated with SIVmacC8 and then challenged with SIVsmE660 to assess protection levels.
Potential Biases
Potential bias due to the limited genetic diversity of the macaques used in the study.
Limitations
The study had a small sample size and may not be generalizable to other populations.
Participant Demographics
Mauritian-derived cynomolgus macaques with limited MHC and TRIM5α allelic diversity.
Statistical Information
P-Value
p<0.005
Confidence Interval
95% CI
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website